Rein Therapeutics, Inc. (RNTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Rein Therapeutics reported revenue of $0. Net income was -$49.9M, or -$1.96 per diluted share. Operating activities generated -$19.4M of cash. At fiscal year end, Rein Therapeutics held $24.2M in total assets against $7.2M in total liabilities, including $3.2M of cash and equivalents.
Open the full interactive Rein Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Rein Therapeutics Key Stats
| Share Price | $0.75 |
|---|---|
| Market Cap | $50.6M |
| 52-Week Range | $0.70 – $1.88 |
| Shares Outstanding | 67.1 million (basic, 2026 Q2) |
Rein Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$20.5M | -$26.6M | -$27.6M | -$16.3M | -$65.1M | -$50.6M |
| Pre-Tax Income | -$21.2M | -$26.2M | -$27.3M | -$15.7M | -$64.4M | -$50.6M |
| Income Tax | $0 | $0 | $0 | $0 | -$1.5M | -$712,000 |
| Net Income | -$21.2M | -$26.2M | -$27.3M | -$15.7M | -$62.9M | -$49.9M |
| Diluted EPS | -$12.20 | -$5.80 | -$6.02 | -$3.42 | -$3.51 | -$1.96 |
Rein Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$5.6M | -$32.0M | -$5.8M | -$6.4M |
| Diluted EPS | -$0.21 | -$1.26 | -$0.19 | -$0.10 |
Rein Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.0M | $3.6M | $5.2M | $17.3M | $12.9M | $3.2M |
| Current Assets | $16.3M | $48.2M | $21.9M | $18.3M | $13.7M | $4.3M |
| Total Assets | $16.3M | $48.5M | $22.0M | $106.0M | $62.2M | $24.2M |
| Current Liabilities | $4.0M | $4.5M | $3.4M | $4.4M | $5.7M | $6.2M |
| Total Liabilities | $4.2M | $4.6M | $3.4M | $7.7M | $7.8M | $7.2M |
| Shareholders' Equity | $12.2M | $43.9M | $18.6M | $6.9M | $54.4M | $16.9M |
Rein Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$20.5M | -$23.8M | -$24.9M | -$19.8M | -$22.3M | -$19.4M |
| Cash From Investing | $6.4M | -$35.9M | $26.5M | $16.2M | $0 | — |
| Cash From Financing | $15.8M | $55.7M | — | $15.8M | $17.8M | $9.8M |
| Free Cash Flow | -$20.5M | -$23.9M | -$25.0M | — | — | — |
Figures from Rein Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Rein Therapeutics financials page for every line item.
Rein Therapeutics Company Profile
| Ticker | RNTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Austin, Texas |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001420565 |
Frequently Asked Questions
What was Rein Therapeutics' revenue in fiscal 2025?
Rein Therapeutics (RNTX) reported revenue of $0 for fiscal 2025.
What is Rein Therapeutics' annual revenue history?
Rein Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Rein Therapeutics' net income in fiscal 2025?
Rein Therapeutics reported net income of -$49.9M for fiscal 2025.
What was Rein Therapeutics' earnings per share (EPS) in fiscal 2025?
Rein Therapeutics' diluted EPS was -$1.96 for fiscal 2025 (adjusted for any later stock splits).
What was Rein Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Rein Therapeutics reported revenue of $0.
How many shares of Rein Therapeutics are outstanding?
Rein Therapeutics reported a weighted average of 67.1 million basic shares outstanding in 2026 Q2.
What is Rein Therapeutics' market cap?
Based on its latest closing price, Rein Therapeutics (RNTX) has a market capitalization of about $50.6M.
When does Rein Therapeutics' fiscal year end?
Rein Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Rein Therapeutics headquartered?
Rein Therapeutics lists its business address in Austin, Texas in its SEC filings.